Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

261. A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events

A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events Hope C, Overhage J M, Seger A, Teal E, Mills V, Fiskio J (...) , Gandhi T K, Bates D W, Murray M D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two methods of identifying drug-related problems in outpatient settings, to determine which problems were adverse drug events (ADEs) and which were

2003 NHS Economic Evaluation Database.

262. Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. Full Text available with Trip Pro

Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. Concern about harm to newborns from early postpartum discharges led to laws establishing minimum hospital stays in the mid-1990s. We evaluated the effects of an early-discharge protocol (a hospital stay of one postpartum night plus a home visit) in a health maintenance organization (HMO) and a subsequent state law guaranteeing a 48-hour hospital stay.Using interrupted-time-series

2002 NEJM

263. The reliability of medical record review for estimating adverse event rates. (Abstract)

The reliability of medical record review for estimating adverse event rates. The data used by the U.S. Institute of Medicine to estimate deaths from medical errors come from a study that relied on nurse and physician reviews of medical records to detect the errors.To measure the reliability of medical record review for detecting adverse events and negligent adverse events.Medical record review.Hospitalizations in Utah and Colorado in 1992.After three independent reviews of 500 medical records (...) , the following were measured: reliability and the effect of varying criteria for reviewer confidence in and reviewer agreement about the presence of adverse events.For agreements in judgments of adverse events among the three sets of reviews, the kappa statistics ranged from 0.40 to 0.41 (95% CIs ranged from 0.30 to 0.51) for adverse events and from 0.19 to 0.23 (CIs, 0.05 to 0.37) for negligent adverse events. Rates for adverse events and for negligent adverse events varied substantially depending

2002 Annals of Internal Medicine

264. Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001

Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001 Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001 Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001 Ernst E Authors' objectives To summarise the reported evidence from case reports of serious adverse events following cervical spine manipulation (CSM). Searching (...) . Outcomes assessed in the review Case reports containing original data of serious adverse events were eligible for inclusion. How were decisions on the relevance of primary studies made? The author selected articles for inclusion in the review. Assessment of study quality The author did not state that they assessed validity. Data extraction The author extracted data for the review. Data were extracted on the nature of the serious adverse event and the clinical outcome, as reported in each individual

2002 DARE.

265. Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings

Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings Hoffmann R, Herrmann G (...) lesions, and lesions in extremely tortuous vessels were ineligible. The second study sample comprised those patients from the first who, after being randomised and treated, had had a successful intervention and no major adverse cardiac event (MACE) within 30 days of the intervention. Setting The setting was hospital. The economic study was conducted in Germany. Dates to which data relate Neither dates for effectiveness and resource use nor the price year were reported. Source of effectiveness data

2002 NHS Economic Evaluation Database.

266. Prescription-event monitoring and reporting of adverse drug reactions. (Abstract)

Prescription-event monitoring and reporting of adverse drug reactions. Newly marketed drugs in the UK are marked with a black triangle, indicating that doctors should report all adverse drug reactions associated with them to the Committee on Safety of Medicines (CSM). However, under-reporting of adverse reactions is frequent. Our aim was to establish what types of adverse reactions are under-reported to the CSM by family doctors who work in England. We used prescription-event monitoring data (...) obtained for 15 newly marketed drugs. Only 9% (376) of 4211 events found on prescription-event monitoring were reported to the CSM. However, 53% (27) of 51 events classified as serious adverse drug reactions were reported. Overall, serious events were five times more likely to be reported to the CSM than non-serious events. Our results should not be extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous reports.

2001 Lancet

267. Adverse events of premixed nitrous oxide and oxygen for procedural sedation in children. (Abstract)

Adverse events of premixed nitrous oxide and oxygen for procedural sedation in children. In France, administration of premixed 50% nitrous oxide and oxygen for procedural sedation is under close supervision by the French Drug Agency before final approval for use. We have examined the frequency of adverse events in children sedated with 50% nitrous oxide and oxygen over a broad range of non-specialised facilities. A mean of 0.33% (SD 0.10) children had major adverse events. Thus, premixed 50

2001 Lancet

268. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. (Abstract)

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Data on adverse events to antiretroviral treatment have been recorded in clinical trials, post-marketing analyses, and anecdotal reports. Such data might not be an up-to-date or comprehensive assessment of all possible treatment combinations defined as potent antiretroviral treatment.Using a standard clinical and laboratory method, we assessed prevalence of adverse events in 1160 patients who (...) were receiving antiretroviral treatment. We measured the toxic effects associated with the drug regimen (protease inhibitor [PI], non-nucleoside and nucleoside analogue reverse transcriptase inhibitor) and specific compounds using multivariate analyses.47% (545 of 1160) of patients presented with clinical and 27% (194 of 712) with laboratory adverse events probably or definitely attributed to antiretroviral treatment. Among these, 9% (47 of 545) and 16% (30 of 194), respectively, were graded

2001 Lancet

269. The measurement and monitoring of surgical adverse events

The measurement and monitoring of surgical adverse events The measurement and monitoring of surgical adverse events The measurement and monitoring of surgical adverse events Bruce J, Russell E M, Mollison J, Krukowski Z H Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bruce J, Russell E M, Mollison J, Krukowski Z H. The measurement (...) and monitoring of surgical adverse events. Health Technology Assessment 2001; 5(22): 1-194 Authors' objectives The aim of this methodological review was to identify a selection of common and potentially avoidable surgical adverse events and to assess whether they could be reliably and validly measured, to review methods for monitoring their occurrence and to identify examples of effective monitoring systems for selected events. This review is a comprehensive attempt to examine the quality of the definition

2001 Health Technology Assessment (HTA) Database.

270. Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited

Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited [42] Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited | Therapeutics Initiative Independent Healthcare Evidence > > [42] Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited A recent paper has documented the under-reporting of safety data in published randomized controlled trials (RCTs). Serious adverse events (SAEs) comprise one component of safety and are potentially the most important outcome measure (...) rhabdomyolysis deaths had been reported and was based partly on the availability of other statins: lovastatin, pravastatin, simvastatin, fluvastatin, and atorvastatin. These other statins have been associated with rhabdomyolysis; it is important that such cases be reported to regulatory authorities. How does SAE analysis relate to the usual way data in RCTs are presented? SAE analysis is particularly relevant for RCTs in which the goal of therapy is to reduce death and life-threatening events, such as lipid

2001 Therapeutics Letter

271. Using an improvement model to reduce adverse drug events in VA facilities

Using an improvement model to reduce adverse drug events in VA facilities Using an improvement model to reduce adverse drug events in VA facilities Using an improvement model to reduce adverse drug events in VA facilities Weeks W B, Mills P D, Dittus R S, Aron D C, Batalden P B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) in the economic analysis The measure of benefit used in the economic analysis was serious or life threatening adverse drug events prevented. These were estimated as the proportion of medication errors that resulted in serious or life threatening adverse drug events multiplied by the observed number of medication errors averted by the QI project. The proportion of medication errors that resulted in serious or life threatening adverse drug events was estimated from 2 published studies. Direct costs A discounted

2001 NHS Economic Evaluation Database.

272. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis

Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis Ross S D, Akhras K S, Zhang S, Rozinsky M, Nalysnyk L Authors' objectives To quantify the frequency of antihypertensive agents being discontinued due to adverse events (AEs), by a meta (...) , 15.7% had diabetes mellitus and 27.4% had left ventricular hypertrophy. Outcomes assessed in the review Trials that reported the number of patients in the treatment and placebo groups who discontinued treatment due to AEs were eligible for inclusion, as this was the primary outcome of interest. The authors also sought information on the timing of discontinuations. A secondary outcome was the frequency of patients with any adverse drug event. The authors used the following definition of adverse drug

2001 DARE.

273. Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events

Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events Villaneuva E Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Villaneuva E. Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2000: 10 Authors' objectives This aim of this critical appraisal was to assess whether peri-operative beta-blockers reduce myocardial ischaemia, myocardial infarction, and death. Project page URL Indexing Status Subject indexing assigned by CRD MeSH

2000 Health Technology Assessment (HTA) Database.

274. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use

Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use Tramer M R, Moore R A, Reynolds D J, McQuay H J Authors' objectives To estimate the incidence of death from (...) Research Student Award; Swiss National Research Foundation, grant number 3233-51939.97; European Union Biomed 2, grant number BMH14 CT95 0172; NHS Research and Development Health Technology Assessment Programme, grant number 94/11/4; Pain Research Fund. Bibliographic details Tramer M R, Moore R A, Reynolds D J, McQuay H J. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85(1-2): 169-182 PubMedID Other

2000 DARE.

275. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. (Abstract)

Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs. However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied.To measure the effect of pharmacist participation on medical rounds in the ICU on the rate of preventable adverse (...) drug events (ADEs) caused by ordering errors.Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention.A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital.Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions

1999 JAMA Controlled trial quality: uncertain

276. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat Tfelt-Hansen P Authors (...) ' objectives To assess the efficacy, speed of onset and adverse events of sumatriptan given using various routes of administration for migraine treatment. Searching The author searched MEDLINE (over the entire date range, performed in April 1997), using the terms 'migraine', 'sumatriptan', and 'clinical trials'. Printouts from the database on clinical trials on sumatriptan were obtained from Glaxo Wellcome Denmark. The journals 'Archives of Neurology', 'Neurology', 'Headache' and 'Cepalalgia' from 1990

1998 DARE.

277. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis

Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis Ross S D, Kupelnick B, Kumashiro M, Arellano F M, Mohanty N, Allen I E Authors' objectives The overall objective was to assess the risk of serious events associated with the use of any formulation of isradipine (...) as monotherapy in hypertension. The specific questions were: 1) Are the major adverse event rates higher with isradipine or isradipine sustained-release than with placebo or active controls? 2) Are the rates of withdrawal due to major adverse events higher with isradipine/isradipine sustained-release than with placebo or active controls? 3) What is the association of isradipine formulations with major adverse events? 4) Are the major adverse event rates from the sponsor's unpublished trials similar

1997 DARE.

278. Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. (Abstract)

Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. 3801 children aged 5-11 months were entered into a blind placebo-controlled trial of pertussis vaccine. 954 were randomised to receive placebo (vaccine solvent), 1419 to receive a two-component vaccine containing formaldehyde detoxified lymphocytosis promoting factor (LPF) and filamentous haemagglutinin, and 1428 to receive an LPF

1988 Lancet Controlled trial quality: predicted high